V. Catterson

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

A. Badley, V. Marconi, F. Cerasoli, 2022, Thorax.

Drivers of Mortality in COVID ARDS Depend on Patient Sub-Type

N. Hajizadeh, L. McCullagh, V. Catterson, 2022, medRxiv.

Phenotype-driven identification of drug targets for post-COVID-19 anosmia

G. Musso, V. Catterson, Yolanda Sanchez, 2022, bioRxiv.

EARLY LENZILUMAB TREATMENT OF COVID-19 PATIENTS USING C-REACTIVE PROTEIN AS A BIOMARKER IMPROVES EFFICACY: RESULTS FROM THE PHASE 3 LIVE-AIR TRIAL

A. Kilcoyne, F. Cerasoli, Z. Temesgen, 2022, medRxiv.